Prostate Cancer
ONECUT2 Activates Diverse Resistance Drivers of Androgen Receptor-Independent Heterogeneity in Prostate Cancer.
November 1, 2023
Focal Therapy with High-Intensity Focused Ultrasound for Prostate Cancer: Three Year Outcomes from a Prospective Trial.
October 31, 2023
Making the Case for Autophagy Inhibition as a Therapeutic Strategy in Combination with Androgen-Targeted Therapies in Prostate Cancer.
October 31, 2023
Safety and tolerability of long-term treatment with darolutamide in patients with metastatic castration-resistant prostate cancer.
October 30, 2023
Biweekly vs Triweekly Cabazitaxel in Older Patients With Metastatic Castration-Resistant Prostate Cancer: The CABASTY Phase 3 Randomized Clinical Trial.
October 30, 2023
Modifiable risk factors for subsequent lethal prostate cancer among men with an initially negative prostate biopsy.
October 30, 2023
Clarity and PSI Kick Off SAR-bisPSMA Phase III
October 27, 2023
Novartis Confirms Unconstrained Supply for Pluvicto® and Continues to Significantly Expand the Number of Treatment Centers
October 27, 2023
Robot-Assisted Surgery and Racial and Ethnic Disparities in Post-Prostatectomy Outcomes Among Prostate Cancer Patients.
October 27, 2023
Towards Improving the Efficacy of PSMA-Targeting Radionuclide Therapy for Late-Stage Prostate Cancer-Combination Strategies.
October 27, 2023
Pelvic irradiation for node-positive prostate cancer after prostatectomy: Long-term results of the prospective PLATIN-4 and PLATIN-5 trials.
October 27, 2023
The long tail of oncogenic drivers in prostate cancer.
October 27, 2023